Laboratory Based Survey Of Acquired Hiv Drug Resistance Using Remnant Viral Load Specimens
Laboratory Based Survey Of Acquired Hiv Drug Resistance Using Remnant Viral Load Specimens Book in PDF, ePub and Kindle version is available to download in english. Read online anytime anywhere directly from your device. Click on the download button below to get a free pdf file of Laboratory Based Survey Of Acquired Hiv Drug Resistance Using Remnant Viral Load Specimens book. This book definitely worth reading, it is an incredibly well-written.
Laboratory-based survey of acquired HIV drug resistance using remnant viral load specimens by Anonim Pdf
WHO’s laboratory-based acquired drug resistance survey method yields robust estimates of acquired HIV drug resistance in adults, children and adolescents taking both dolutegravir and non-dolutegravir based regimens by genotyping remnant specimens from routine viral load testing. Results are used to inform programme decision making regarding optimal ART regimens and support evaluation of programme quality with respect to maximizing viral load suppression and minimizing emergence of resistance in people taking ART.
Author : World Health Organization Publisher : World Health Organization Page : 28 pages File Size : 49,8 Mb Release : 2022-11-22 Category : Medical ISBN : 9789240063204
Sentinel surveys of acquired HIV resistance to dolutegravir among people receiving dolutegravir-containing antiretroviral therapy by World Health Organization Pdf
Author : World Health Organization Publisher : World Health Organization Page : 30 pages File Size : 45,9 Mb Release : 2023-09-12 Category : Medical ISBN : 9789240076662
Target product profile for HIV drug resistance tests in low- and middle-income countries: Africa by World Health Organization Pdf
HIV-1 drug resistance tests may be useful tools for optimizing ART regimens when used in the context of information about viral load, immune and clinical status, adherence practices and available treatment options. Several types of drug resistance tests are available, either as commercial kits or based on published methods for in-house assays. The target product profile for HIV drug resistance tests in low- and middle-income countries: Africa is designed to guide the development of new HIV drug resistance tests in the era of dolutegravir-based antiretroviral therapy (ART) and to facilitate the evaluation of the suitability of currently available HIV drug resistance tests for specific applications. The target product profiles focus on the new-term future for available ART regimens and their use and anticipates an innovate test that will meet the projected demand.
Author : World Health Organization Publisher : World Health Organization Page : 46 pages File Size : 50,5 Mb Release : 2024-03-01 Category : Medical ISBN : 9789240086319
HIV drug resistance by World Health Organization Pdf
This brief report summarizes recent information on HIV drug resistance (HIVDR) in the era of integrase-strand transfer inhibitors (INSTI) for HIV prevention and treatment. In this report, WHO documents high levels of HIV viral load suppression (>90%) in populations receiving dolutegravir (DTG)-containing antiretroviral therapy (ART). However, recent observational data reveal that HIVDR to DTG is emerging at levels exceeding those observed in clinical trials. Few countries have reported people not achieving viral suppression while receiving DTG-containing ART. However, amongst the surveys reported, levels of DTG resistance ranged from 3.9% to 8.6%, with levels as high as 19.6% observed among highly treatment-experienced people who transitioned to a DTG-containing ART while having high HIV viral loads. Levels of observed DTG resistance in real world populations receiving ART appear to be higher than anticipated from clinical trials. WHO recommends that countries routinely implement standardised surveillance of HIVDR to follow the prevalence and patterns of resistance among people not achieving suppressed viral load. The use of long acting cabotegravir (CAB-LA) for pre-exposure prophylaxis (PrEP) greatly reduces the risk of acquiring HIV. However, INSTI resistance has been observed in some cases with recent CAB-LA exposure, and delayed detection and confirmation of HIV infection can increase the risk of selection of INSTI drug resistance–associated mutations. Despite the possible risk, the roll-out of CAB-LA for PrEP should not be hindered. Scale-up of PrEP should be accompanied by standardized surveillance of drug resistance among people testing positive for HIV while receiving PrEP.
Author : World Health Organization Publisher : World Health Organization Page : 40 pages File Size : 45,5 Mb Release : 2023-05-01 Category : Medical ISBN : 9789240071087
Author : World Health Organization Publisher : World Health Organization Page : 592 pages File Size : 43,7 Mb Release : 2021-07-16 Category : Medical ISBN : 9789240031593
Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring by World Health Organization Pdf
These consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring bring together existing and new clinical and programmatic recommendations across different ages, populations and settings, bringing together all relevant WHO guidance on HIV produced since 2016. It serves as an update to the previous edition of the consolidated guidelines on HIV. These guidelines continue to be structured along the continuum of HIV care. Information on new combination prevention approaches, HIV testing, ARV regimens and treatment monitoring are included. There is a new chapter on advanced HIV disease that integrates updated guidance on the management of important HIV comorbidities, including cryptococcal disease, histoplasmosis and tuberculosis. The chapter on general HIV care, contains a new section on palliative care and pain management, and up to date information on treatment of several neglected tropical diseases, such as visceral leishmaniasis and Buruli ulcer. New recommendations for screening and treating of cervical pre-cancer lesions in women living with HIV are also addressed in this chapter. Guidance on service delivery was expanded to help the implementation and strengthening the HIV care cascade. Importantly, this guidance emphasizes the need for differentiated approaches to care for people who are established on ART, such as reduced frequency of clinic visits, use of multi-month drug dispensing and implementation of community ART distribution. The adoption of these efficiencies is essential to improve the quality of care of people receiving treatment and reduce the burden on health facilities, particularly in resource limited settings.
Author : World Health Organization Publisher : World Health Organization Page : 34 pages File Size : 46,7 Mb Release : 2022-06-30 Category : Medical ISBN : 9789240053038
Author : World Health Organization Publisher : World Health Organization Page : 424 pages File Size : 43,8 Mb Release : 2022-07-29 Category : Medical ISBN : 9789240055315
Consolidated guidelines on person-centred HIV strategic information by World Health Organization Pdf
These consolidated guidelines are aimed at supporting the generation of responsive person-centred data from routine national health management information systems across the HIV cascade, from prevention, testing and treatment to longer-term health care. They build upon the 2017 Consolidated guidelines on person-centred HIV patient monitoring and case surveillance, which describe information that should be collected in primary HIV patient monitoring tools, and the 2020 Consolidated HIV strategic information guidelines, which cover aggregate indicators for managing and monitoring programmes. The purpose of this guideline consolidation is to provide the recommended data elements, indicators and guidance on data systems and their use across the spectrum of health sector HIV services in one place. This document focuses on strengthening the analysis and use of routine data at each stage of the cascade and emphasizes?/addresses? person-centred HIV prevention, testing and treatment, integration of HIV-related infections, the use of routine surveillance data to measure impact, and the development and use of digital health data systems and their governance. It also identifies the gaps and limitations in these data, and the need for strengthening the use of data in all HIV-related strategic information, including population-based surveys, modelling, community-led monitoring and other sources.
King K. Holmes,Stefano Bertozzi,Barry R. Bloom,Prabhat Jha
Author : King K. Holmes,Stefano Bertozzi,Barry R. Bloom,Prabhat Jha Publisher : World Bank Publications Page : 506 pages File Size : 40,6 Mb Release : 2017-11-06 Category : Medical ISBN : 9781464805257
Disease Control Priorities, Third Edition (Volume 6) by King K. Holmes,Stefano Bertozzi,Barry R. Bloom,Prabhat Jha Pdf
Infectious diseases are the leading cause of death globally, particularly among children and young adults. The spread of new pathogens and the threat of antimicrobial resistance pose particular challenges in combating these diseases. Major Infectious Diseases identifies feasible, cost-effective packages of interventions and strategies across delivery platforms to prevent and treat HIV/AIDS, other sexually transmitted infections, tuberculosis, malaria, adult febrile illness, viral hepatitis, and neglected tropical diseases. The volume emphasizes the need to effectively address emerging antimicrobial resistance, strengthen health systems, and increase access to care. The attainable goals are to reduce incidence, develop innovative approaches, and optimize existing tools in resource-constrained settings.
